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OBJECTIVE: The objective of this selective EBM review is to determine whether or not CT-
P13 is as good as infliximab in controlling pain in adult patients with rheumatoid arthritis. 
 
STUDY DESIGN: A review of three double-blind randomized controlled trials that were 
published in English after 2008 were used.  
 
DATA SOURCES: Data sources include peer reviewed articles that were published on PubMed 
database. They were selected based on their relevance to the research question as well as patient 
measured outcomes. 
 
OUTCOMES MEASURED: The outcomes measured include efficacy of the drug measured 
through Visual Analog Scale (VAS), pain on DAS28 scale and pain on the ACR20 scale. 
 
RESULTS: All three studies found that CT-P13 was as effective in reducing pain when 
compared to infliximab in treating rheumatoid arthritis. One study found that the mean change 
from baseline using the VAS +/- SD was -30.2 +/- 28 for CT-P13 and was -28 +/- 26.9 for 
infliximab with a 95% CI (Yoo DH, Racewicz A, Brzezicki J, et al. Arthritis Res Ther. 2016;18. 
doi: 10.1186/s13075-016-0981-6). Another study compared the change in the DAS28 score and 
saw the mean decrease from baseline of 2.2 with infliximab and 2.1 with CT-P13 with a CI of 
95% (Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin 
KE, Mørk C, Jahnsen J, Kvien TK, Lancet. 2017;389(10086):2304-2316 doi: 10.1016/S0140-
6736(17)30068-5). In Yoo, Prodanovic, Jaworski J, et al. the mean change in VAS from week 54 
to week 102 for the maintenance group and switch group was -1.1 and -2.6 (Ann Rheum Di. 
2017;76(2):355-363. doi: 10.1136/annrheumdis-2015-208786).  
 
CONCLUSION: Two studies were able to statistically show that CT-P13 was able to improve 
pain as well as infliximab and one study results were inconclusive as to whether CT-P13 was as 
effective as infliximab in controlling pain in patients with RA 
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INTRODUCTION 
 Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease. It effects the 
lining of the joints, starting in small joints and spreading to larger ones. Over time, it can lead to 
erosion of the bone and cause irreversible joint deformities. The disease can wax and wane in 
severity from patients having a flare to being in relative remission.1 RA can have a systemic 
effect on the body damaging things such as the blood vessels, heart, lungs, kidneys, eyes, nerves, 
and skin.1 It affects about 1% of the population and affects women more than men in a 3:1 ratio.2  
The specific cause of RA is unknown, however, the incidence and severity of RA has 
been linked with multiple genes including HLA DRB1 being the best genetic risk factor.3 Along 
with genetic components, there are some environmental factors, such as cigarette smoking, 
connected to an RA diagnosis.4 Rheumatoid arthritis can range in severity making it hard to find 
an exact number of healthcare visits patients utilize yearly. A report from 2013 states there were 
over 105.7 million healthcare visits for arthritis and other rheumatic conditions (AORC).5 That 
same study shows that RA is the 3rd most common cause for hospitalization for people with 
AORC.5 An exact number for the total healthcare cost of rheumatoid arthritis has not been 
calculated since 2005, but at that time the annual cost for the disease was $39.2 billion.6 
RA is generally managed by rheumatologists, but because the disease can present as a 
systemic disease, it can be seen and managed by many practitioners in the medical field.2 Since 
RA is a progressive disease it is normally treated in a stepwise fashion. It is initially treated with 
disease modifying antirheumatic drugs (DMARDs).3 During flares or while the patient is waiting 
for the DMARD to take effect, a low dose corticosteroids can be used to reduce inflammation.3 
NSAIDs can be used to treat pain alongside DMARDs, but cannot be used as monotherapy.3 
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Biologics such as infliximab can be used alone or in combination with oral DMARDs for 
patients who have failed initial DMARD therapy.3  
Infliximab and other biologics have been used for many years to treat diseases such as 
RA. Due to increasing prices of medicine and the recent expiration of the infliximab patent, new 
biosimilars like CT-P13 are being proposed to treat RA the same way as infliximab but at a 
lower cost.7 A 100mg vial of reconstituted Infliximab cost $1,401.38 and a 100mg vial of 
reconstituted CT-P13 is $1,135.54.8 The patient will use multiple vials per treatment and will 
need treatments at 0, 2, 6 weeks and every 8 weeks after that.8 If a patient uses CT-P13 it can 
save the patient thousands of dollars over the span of the disease relieving some of the burden of 
healthcare costs.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not CT-P13 is as 
good as infliximab in controlling pain in adult patients with rheumatoid arthritis. 
METHODS 
 The articles were published after 2008 and in English. They were narrowed down using 
keywords such as “Infliximab,” “biosimilar,” and “anti-inflammatory disease.” The articles were 
then chosen based on their relevance to the clinical question and whether their outcomes were 
patient oriented evidence that matters (POEMS). Inclusion and exclusion criteria were used 
while searching for these articles. To help identify relevant articles, the following inclusion 
criteria was used: RCTs, published in 2008 and later, human subjects, CT-P13, infliximab, and 
inflammatory disease. Exclusion criteria were other biosimilars, other languages, and anything 
published before 2008. Table 1 displays the inclusion and exclusion criteria used in each study. 
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Values reported in the studies that were relevant to the clinical question were the confidence 
interval (CI), mean change from baseline, and standard deviation and change from baseline. 
Three double blind randomized control trials (RCT) articles were used for this EBM 
review. They focused on adults with rheumatoid arthritis between 18-75 years old. The 
intervention being observed in each study was CT-P13 treatment and the comparisons were 
patients being given infliximab or switching patients from infliximab to CT-P13. The outcome 
measured in these studies was pain reduction using the visual analog scale (VAS), the DAS28 
scale, and the ACR20.  
TABLE 1.  Demographics & Characteristics of included studies 
 











RCT 606 18-75  Pts with RA ≥1 
year, active 
disease that did 
not respond 
adequately to 
MTX for ≥ 3 
months 
Pts who did not have active 
diseases, not in age range ,or 
responded to MTX.  
151 2hr IV infusion 
of CT-P13 or 
infliximab at 
week 0, 2, & 6, 
then every 8 




















nursing female,  





during the last 6 
months, Subject 
capable of 
Major co-morbidities, such as 
severe malignancies, severe 
DM, severe infxs, 
uncontrollable HTN, severe 
CVD, severe respiratory 
diseases and/or other diseases 
including inflam conditions for 
which infliximab is 
contraindicated. Change of 
major co-medication during 
the last 2mo prior to 
randomization: Inadequate 
birth control, pregnancy, 
and/or breastfeeding. 
Psychiatric or mental 
disorders, alcohol abuse or 
other substance abuse, 
language barriers or other 
factors which makes adherence 
to the study protocol 
impossible Change in 
treatment with innovator 
infliximab during the last 6 
months due to disease related 





infusions on set 
schedule 
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understanding 








factors, not including 
dose/frequency adjustments 
due to drug concentration 
measurements For patients 
with UC and CD: Functional 
colostomy or ileostomy. 
Extensive colonic resection 
with less than 25 cm of the 
colon left in situ 
Yoo, 
201710 




Not signing new informed 
consent, pts from institutions 
that did not approve the study  




Outcomes were measured using VAS, DAS28 scores, and ACR20 scores. The VAS scale 
allowed the patients to rate their pain on a scale of 0 (being no pain) and 100 (being worst pain 
imaginable). In Yoo DH, Racewicz A, Brzezicki J, et al mean change in VAS outcomes were 
measured at baseline, week 14, week 30 and week 546 and in Yoo DH, Prodanovic N, Jaworski J, 
et al they were measured at week 54 and week 102.10 Each new measurement from the scale was 
compared to the patient’s baseline to see if there was any difference in improvement between the 
treatments. The DAS28 score measures the disease activity state of 28 joints. The score is 
calculated by counting the number of swollen joints, counting the number of tender joints, taking 
blood to measure the ESR or CRP, and asking the patient to make a ‘global assessment of 
healthcare.11 The DAS28 scale was measured at baseline and at 52 weeks and included the 
change from baseline. 9 The American College of Rheumatology 20 (ACR20) is measured as a 
20% improvement in the number of tender and swollen joints, and a 20% improvement in three 
of the five criteria: patient global assessment, physician global assessment, functional ability 
measure, visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein.12 
RESULTS 
 Three double blind randomized control trials were assessed to see if CT-P13 was as good 
as infliximab in controlling pain in adult patients ages 18-75 years old with rheumatoid arthritis. 
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Yoo, Racewicz , Brzezicki, et al. separated patients with 1:1 ratio giving half CT-P13 and half 
infliximab and measured their mean change in pain over 54 weeks.6 Jørgensen performed a 
crossover, taking patients who had been on infliximab for at least 6 months and switching half of 
them to start CT-P13 while leaving the other half to remain on infliximab.9 Yoo, Prodanovic, 
Jaworski, et al. did a crossover study using the patients from the initial phase III clinical trial 
who had completed the 54 weeks of treatment. They continued the CT-P13 patients on their CT-
P13 regimen and switched the patients who were on infliximab to CT-P13.10 Each of these 
studies measured the patients’ improvement by monitoring their change in pain from baseline 
either by VAS or DAS28.10  
 The Yoo, Racewicz , Brzezicki, et al. study enrolled 606 subjects with active RA that had 
failed methotrexate treatment alone to receive either CT-P13 or infliximab.6 Baseline 
demographics and characteristics were similar between the two groups.6 Patients received 
methotrexate and folic acid weekly and 2 hour infusions of either CT-P13 or infliximab at week 
0, 2, 6, and then every 8 weeks up to week 54.6 Patients were premedicated with antihistamines 
at the discretion of the investigator. 6 The study measured change in VAS score at baseline, week 
14, week 30 and week 54 to evaluate the results of the interventions.6 In this study the mean 
change of pain between baseline and week 54 +/- SD was -30.2 +/- 28 for CT-P13 and was -28 
+/- 26.9 for infliximab.6 Table 2 has a summary of the results below. The efficacy of this study 
was decided if the CI of 95% for treatment difference was within +/-15% and it was between 6-
10%, effectively showing that the estimate of treatment effect was precise.6 These results 
allowed the authors to confidently say the CT-P13 treatment had comparable efficacy to 
infliximab in treating pain in patients who have RA up to week 54.6 Adverse events from the 
study were similar between the two groups.6  
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TABLE 2. VAS results measuring change in pain for Yoo, Racewicz , Brzezicki, et al.6 
 
 VAS score for the 
patient baseline 
assessment of pain 
VAS score for the 
patient assessment of 
pain week 54 
VAS score for the 
patient assessment of 
pain change from 
baseline 
95% CI  
CT-P13 65.7+/-17.8 35.0 +/- 21.2 -30.2 +/-23.8 6-10% 
 infliximab 65.5 +/- 17.7 37.4 +/- 24.7 -28.4 +/- 26.9 
 The Jørgensen et al. study enrolled 482 subjects with autoimmune diseases including 
Crohn’s disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and 
chronic plaque psoriasis, who had been on infliximab for at least 6 months, and randomly 
assigned them to either continue treatment with infliximab or switch to CT-P13.9 Both treatment 
groups were similar for baseline demographics and disease characteristics.9 Number of infusions 
varied depending on treatment regimen between infusions every 4 weeks (14 total infusions) to 
infusions ever 12 weeks (5 total infusions).9 The study measured the results of the intervention 
by looking at the change in the DAS28 score between baseline and 52 weeks.9 This study 
combined the DAS28 score for rheumatoid arthritis and psoriatic arthritis.9 For infliximab, the 
DAS28 score changed from 2.5 at baseline to 0.3 and for CT-P13 it changed from 2.2 at baseline 
to 0.1, as seen in table 3 below. The efficacy of this study was decided if the CI of 95% for 
treatment difference was within 15% and it was between -.07-0.61%, effectively showing that 
the estimate of treatment effect was precise. The results of this study show that switching from 
infliximab to CT-P13 was similar to continuing the patient on the infliximab treatment.9 The rate 
of adverse events reported in this study was comparable between the two drugs.9  
TABLE 3. Measuring change in DAS28 score for Jorgensen et al.9 
 DAS28 score 
baseline 
DAS28 score at 52 
weeks 
Difference at 52 
weeks 
95% CI  
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CT-P13 2.2 0.1 0.27 -.07-0.61% 
infliximab 2.5 0.3 
  
 The Yoo, Prodanovic, Jaworski, et al. study was a crossover study from his original 
study, this time looking at the effects of switching from infliximab to CT-P13. The study 
enrolled 302 participants that had previously completed the 54 weeks phase III trial, 158 
continued CT-P13 and 144 who switched from infliximab to CT-P13.10 All patients were 
concomitantly treated with methotrexate and folic acid. 10 Both treatment groups were similar for 
baseline demographics and disease characteristics. 10 The study looked at the results by 
measuring a mean decrease in VAS score from baseline, which was prior to the treatment 
received in the clinical trial, at week 54, now defined as the beginning of this trial, and week 102, 
end of this trial.10 The patients who remained on CT-P13 had a mean decrease in VAS from 
baseline of 32.4 compared to a mean decrease of 35 from baseline with the group who switched 
from infliximab to CT-P13.10 The data is shown in table 4 below.10 The value of this study was 
determined by the response rates measured with the ACR20.10At week 102 there was a 71.7% 
response rate in the maintenance group and 71.8% response rate for the switch . 10 The efficacy 
of this study was decided if the CI of 95% for treatment difference was within 15% and it was 
between -10-10%, effectively showing that the estimate of treatment effect was precise (Table 
5).10 Adverse events that occurred during the extension study were fairly similar between the 
maintenance group and the switch group.10 
 
TABLE 4. VAS results measuring change in pain for Yoo, Prodanovic, Jaworski, et al. 10 
 





VAS score for the 
patient assessment 
of pain change from 
baseline at week 54 
VAS score for the 
patient assessment 
of pain change 





week 54 and 
week 102 
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65.8 -32.4 -35 -2.6 
 
TABLE 5. Measuring response rate in ACR20 score for Yoo, Prodanovic, Jaworski, et al 10  
 
 ACR20 response 
rate at week 102 
95% CI 
Pt staying on CT-P13 (maintenance group) 71.7% -10-10% 




 Infliximab and its biosimilar CT-P13 are tumor necrosis factor inhibitors.6 By way of 
their mechanism of action and as seen in the studies above the most common side effects were 
infections. The infections ranged from latent tuberculosis (TB), upper respiratory tract infections 
(URTI), urinary tract infections (UTI), lower respiratory tract infections (LRTI), flare in RA 
activity, and herpes virus infection.6, 9, 10  Other common adverse reactions were infusion 
reactions, elevated LFTs, headaches, and abdominal pain but they were similar between the two 
drugs. 6, 9, 10 The amount of adverse reactions reported in the studies was marginal and there was 
limited for safety with use of either CT-P13 or infliximab. 
DISCUSSION 
 Infliximab is a biologic commonly used to treat rheumatoid arthritis refractive to prior 
treatment with DMARDs.3 As discussed above, infliximab has become increasingly more 
expensive. Fortunately, its patent has recently ended, allowing for the  creation of biosimilars 
such as CT-P13. CT-P13 was FDA approved for use in the United States in 2016 and goes by the 
brand name Inflectra.13 It is contraindicated to use CT-P13 >5mg/kg in patients with moderate to 
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severe heart failure and in patients who are allergic to infliximab, have known history of allergies 
to inactive components of CT-P13 or to any murine proteins.13  CT-P13 has a black box warning 
for 1) increased risk of serious infections leading to hospitalizations or death, 2) lymphoma and 
other malignancies some fatal have been noted in children and adolescents treated with tumor 
necrosis factor blockers, and 3) hepatosplenic T cell lymphoma has been noted in patients who 
almost all had been concomitantly treated with azathioprine or 6 mercaptopurine at or prior to 
diagnosis.13 CT-P13 is FDA approved for use in adult and pediatric crohn’s, adult ulcerative 
colitis, rheumatoid arthritis in combination with methotrexate, ankylosing spondylitis, psoriatic 
arthritis, and plaque psoriasis. Currently the FDA does not allow biosimilars to be substituted for 
the biologics at the pharmacy level.14 Practitioners must specifically prescribe the biosimilar.15 
Rheumatoid arthritis is a lifelong disease and patients can be on biologics for years. A limitation 
in the studies was the high losses to follow up of 25% in Yoo DH, Racewicz A, Brzezicki J, et al. 
and 13% in Yoo DH, Prodanovic N, Jaworski J, et al. Another limitation was Jørgensen et al did 
not do an intent to treat analysis. Having high losses to follow up and no doing an intent to treat 
analysis can decrease the validity of these studies. Another limitation was length of follow up. 
Throughout the studies it was shown that CT-P13 had the same efficacy as infliximab when 
treating pain in patients with RA, but the studies stopped at either one or two years. There was no 
long term follow up to see if the efficacy remains the same or if there is an increased risk for 
immunogenicity the longer someone is on the medication.  
CONCLUSION 
 Yoo DH, Racewicz A, Brzezicki J, et al. and Yoo DH, Prodanovic N, Jaworski J, et al. 
randomized control trial and his crossover study showed that CT-P13 was as effective as 
infliximab in controlling pain in adult patients between 18-75 years old with RA. The studies 
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showed that pain control was comparable, and risk of adverse reactions were similar when 
comparing treatment with CT-P13 and infliximab.  The Jørgensen study looked at multiple 
autoimmune diseases, not specifically RA, which may have led to a greater influence on the 
results being favorable for the RA patients. Further research can be done to see if premedicating 
all patients with antihistamines prior to infusions decrease infusion reactions. Further crossover 
studies should be done between the two biologics to further evaluate efficacy, and safety 
(including risk of development of immunogenicity). Doing further research to explore the 
limitations of the prior studies will help solidify the results and instill confidence in the 
practitioners’ judgment to alter traditional treatment methods for maximum patient benefit.  
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